Advertisement

OB/GYN General

Olaparib & Neratinib Synergistic Activity in USC Overexpressing HER2/neu

Sep 15, 2022

The aggressive endometrial cancer subtype known as uterine serous carcinoma (USC) has a dismal survival rate. In advanced/recurrent HER2/neu-positive USC, trastuzumab is a known target because approxi...

Genetic Variants: Multigene Panel Testing of UC Patients

Sep 15, 2022

Historically, Lynch syndrome genes or PTEN have been linked to hereditary uterine cancer (UC); however, there is mounting evidence that other genes have a role and may offer novel clinical therapy opt...

Predictive Biomarker for Surgical Outcome in Advanced Primary HGSOC Patients

Sep 15, 2022

A substantial death rate is linked to high-grade serous ovarian cancer (HGSOC), the most frequent subtype of ovarian cancer. Surgical success or failure is a major indicator of long-term health. Prese...

ADAR1 and AZIN1 RNA Editing Function as an Oncogene & Contributes to EC Immortalization

Sep 15, 2022

It has recently come to light that the epigenetic alteration of adenosine to inosine (A-to-I) RNA editing is a critical carcinogenic process in human malignancies. Its clinical importance and function...

Adjuvant Therapy Utilization and Outcomes for Stage II and III uLMS

Sep 15, 2022

It is still unclear what the best adjuvant treatment for uterine leiomyosarcoma (uLMS) is. Researchers assessed the rate at which stage II and stage III uLMS patients received adjuvant chemotherapy an...

Women with Cervical Cancer and The Use of Hypnotics - A Population-Based Cohort Study

Sep 14, 2022

For a study, researchers sought to determine whether or not women who have been diagnosed with cervical cancer had a higher risk of using hypnotics, and we also found risk indicators for persistent us...

Survival Rates for Cervical Cancer Patients with FIGO Stage IVA

Sep 14, 2022

Cervical cancer in FIGO stage IVA is rare and carries a dismal prognosis. Overall survival (OS) in these patients is low despite the use of PET/CT for staging, concomitant treatment, and image-guided ...

Does Serum Human Epididymis Protein 4 (HE4) Support Referring an Ovarian Mass Patient to an Oncology Center?

Sep 14, 2022

For a study, researchers sought to evaluate the accuracy of human epididymis protein 4 (HE4) in distinguishing benign or borderline from malignant tumors in patients presenting to general hospitals wi...

Retroperitoneal Staging of Endometrial Cancer: Evaluating Long-Term Outcomes

Sep 14, 2022

In recent years, sentinel node mapping (SNM) has become increasingly popular as a treatment for clinically evident early-stage endometrial cancer (EC). Here, researchers looked at and examined how wel...

Adjuvant Chemotherapy Is Associated with Worse Survival for Patients with FIGO Stage I Epithelial Ovarian Carcinoma

Sep 14, 2022

One of the proposed quality metrics for patients with epithelial ovarian cancer  (EOC) is the provision of adjuvant chemotherapy within 42 days of surgery. The purpose of this research was to determi...

Measure of Ovarian Symptoms and Treatment (MOST) describes ovarian symptoms and Treatment

Sep 14, 2022

Patients with recurrent ovarian cancer (ROC) can evaluate the efficacy and safety of palliative chemotherapy by using the Measure of Ovarian Symptoms and Treatment (MOST) concerns; a validated patient...

The ORR with Pembrolizumab in KEYNOTE-158 Was 48% For Previously Treated MSI-H/Dmmr Endometrial Cancer (EC)

Sep 14, 2022

In the multicohort phase 2 KEYNOTE-158 study, pembrolizumab showed an objective response rate clinically significant in patients with advanced MSI-H/dMMR endometrial cancer who had had prior treatment...

In Patients with High-Risk Histologic Endometrial Cancer, Minimally Invasive Surgery Versus Open Surgery

Sep 14, 2022

For a study, researchers sought to evaluate the efficacy of minimally invasive surgery (MIS) versus open surgery (OPS) in reducing the risk of recurrence and death from endometrial cancer (EC) in pati...

Efficacy and Safety of Niraparib Plus Bevacizumab as First-Line Maintenance Therapy

Sep 14, 2022

For a study, researchers sought to evaluate the efficacy and safety of niraparib plus bevacizumab as a first-line maintenance treatment for patients with newly diagnosed advanced ovarian cancer. Patie...

The Efficacy and Safety of Pembrolizumab in Patients with Previously Treated Advanced Vulvar Squamous Cell Carcinoma

Sep 14, 2022

For a study, researchers sought to find a few alternatives for treating advanced vulvar carcinoma. Patients in phase 2 multicohort, open-label KEYNOTE-158 study with advanced vulvar squamous cell carc...

TCS Role in Recurrent Epithelial Ovarian Cancer

Sep 14, 2022

Tertiary cytoreductive surgery (TCS) for recurrent ovarian cancer was studied to determine its clinical efficacy. You can search MEDLINE, PubMed, Embase (Elsevier), ClinicalTrials.gov, Scopus (Elsevie...

ECC: LAVRH as a Safe Option for Minimal Invasive Surgery

Sep 14, 2022

Radical hysterectomy and pelvic lymphadenectomy were found to be the gold standard treatments for early-stage cervical cancer  (ECC) in a study. Recent prospective randomized trial results have spark...

Type of Cancer Treatment & Physical Activity with Psychosocial Outcomes

Sep 14, 2022

Although 1 study found a correlation between vigorous exercise and improved cancer survival, it was unclear which patients would reap the greatest benefits from taking up a more active lifestyle. Rese...

MOABP in Ovarian Cancer Debulking

Sep 14, 2022

Ovarian cancer patients who have their bowels removed as part of cytoreductive surgery (CRS) may benefit from a study looking into the aftereffects of this procedure using a combination of mechanical ...

Abdominal Closure Protocol and SSI After Hysterectomy

Sep 14, 2022

The purpose of this study was to examine the relationship between the use of a strategy for abdominal closure and the occurrence of surgical site infection (SSI) in gynecologic oncology patients under...

SUBSPECIALTIES

Advertisement